Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartwatch replace doctor visits for cancer patients?

NCT ID NCT05018208

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a wearable device and smartphone app can monitor cancer patients' vital signs and symptoms as well as standard in-clinic checks. About 100 patients with various cancers participated, either after CAR-T cell therapy or during radiation treatment. The goal was to see if remote monitoring could detect problems like cytokine release syndrome or neurotoxicity, and to understand how often false alerts occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wearable device and smartphone app
What this could lead to
If successful, this could show that remote monitoring is a reliable way to track cancer patients' health from home, potentially reducing hospital visits.
What could go wrong
This is a small, completed study focused on feasibility and accuracy, not on improving outcomes. The technology may not work as well as in-person assessments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Dec 2021

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing standard of care CAR-T cell therapy in the outpatient setting at Mayo Clinic. Patients undergoing standard of care radiation for (1) head and neck, (2) lung, or (3) gastrointestinal malignancies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ARM 1: Age \>= 18 years * ARM 1: Provide written informed consent * ARM 1: Patients undergoing commercial CAR-T cell therapy in an outpatient setting * ARM 2: Age \>= 18 years * ARM 2: Provide written informed consent * ARM 2: Patients with a plan to undergo radiation therapy for lung, gastrointestinal, or head and neck cancer Exclusion Criteria: * ARM 1: Non-English speaking * ARM 1: Planned initiation of lymphodepleting chemotherapy in the inpatient setting * ARM 2: Non-English speaking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm head and neck carcinoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck carcinoma Hematopoietic and lymphoid cell neoplasm Lung carcinoma Malignant digestive system neoplasm Malignant solid neoplasm

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.